NCT02331368View on ClinicalTrials.gov

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Autologous Stem Cell Transplant

DRUG

Melphalan

140-200 mg/m\^2

DRUG

Lenalidomide

5-15 mg/day starting 45-90 days post-transplant

DRUG

MK-3475

200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.

Trial Locations (2)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT02331368 - Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | Biotech Hunter | Biotech Hunter